Four months after patient death, FDA's hold lifted on Alnylam's fitusiran
The FDA has lifted its clinical hold on Alnylam’s blood clotting drug fitusiran following a four-month standstill.
The company’s Phase II and Phase III studies …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
